Rhucin (recombinant human C1 inhibitor)
- Region
- 🇪🇺 EU
- Active substance
- recombinant human C1 inhibitor
- Company
- Pharming Group N.V.
- Status
- Refused
- Therapeutic area
- Angioedema
- CHMP opinion
- Thu 13 Dec 2007
- Application
- EMEA/H/C/000769
- ATC
- B06C
- Official record
- www.ema.europa.eu
Indication
Replacement treatment in acute attacks of angioedema in patients with congenital C1INH activity deficiency.
Regulatory milestones
No milestones recorded in the last year.
Follow Rhucin
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.